RxDoctor Payments Data

Mark Wolfe, MD

Cardiovascular Disease · Hyannis, MANPI 1962500322

Payments from drug & device makers

$2,697in general payments, 2019–2025

Across 138 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$434
  • Amgen$402
  • Pfizer$269
  • Johnson & Johnson$216
  • E.r. Squibb & Sons, L.L.C.$178
  • Novo Nordisk$161
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$2,65698%
  • Education$412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,697 in reported general payments places this provider in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$695,937
Medicare patients
2,602
Services billed
11,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,240$1,683,046
XareltoRivaroxaban574$779,605
EntrestoSacubitril/Valsartan337$501,685
JardianceEmpagliflozin116$135,231
Repatha SureclickEvolocumab140$130,903
MultaqDronedarone Hcl60$101,886
Metoprolol Succinate2,598$53,058
Praluent PenAlirocumab61$46,903
FarxigaDapagliflozin Propanediol29$39,862
Atorvastatin Calcium2,195$32,512
Rosuvastatin Calcium876$28,917
Ezetimibe458$22,943
Ranolazine ErRanolazine95$17,069
Lisinopril1,424$12,690
Pravastatin Sodium464$12,079

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$269$1,683,0461,240 claims
Johnson & JohnsonXarelto$216$779,605574 claims
NovartisEntresto$434$501,685337 claims
Boehringer IngelheimJardiance$118$135,231116 claims
AstraZenecaFarxiga, Brilinta$55$50,50340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →